Products and Pipeline

Products

Our goal is to develop small-molecule and protein best-in-class therapies that may significantly extend and improve the quality of life for those living with muscle diseases. We always put people first. That’s why we’re targeting areas of high unmet medical need with a sense of urgency while remaining open-minded and flexible so we can find new treatments as quickly as possible.

Progress

Sarcomatrix is committed to developing Laminin-111 as a potential treatment for LAMA2-RD and is seeking funding to complete the pre-clinical work and advance the program to human studies as soon as reasonably possible.

Our small molecule α7β1 integrin activators have shown promise in mouse models stimulating muscle regeneration and may support many forms of muscular dystrophy including Duchenne, Beckers, Emery-Dreifuss, Facioscapulohumeral, Limb-Girdle and many forms of Congenital muscular dystrophy.

α7β1 Integrin Activators

Small molecule α7β1 integrin activators, discovered by our co-founders at the University of Nevada, Reno, have shown promise in mouse models stimulating muscle regeneration. They may support many forms of muscular dystrophy including Duchenne, Beckers, Emery-Dreifuss, Facioscapulohumeral, Limb-Girdle, and many forms of congenital muscular dystrophy.

Protein Replacement

Laminin is a major component of the Extracellular Matrix (ECM) and plays an important role in muscle development and disease. Laminin provides mechanical stability to muscle fibers and is involved in signaling pathways that regulate muscle differentiation, migration, and growth. In addition, laminin is important for maintaining the integrity of the basement membrane, which separates muscle fibers from connective tissue.

We Believe Polytherapy is Key

The future of gene and cell therapy for muscular dystrophy is exciting, and further advancements in these fields hold promise for the development of effective treatments for these debilitating diseases. Sarcomatrix fully supports development of gene and cell therapies and looks forward to the day the cure afflicted individuals. Until that day comes, we’re committed to polytherapy.

Polytherapy involves using multiple treatments in combination to achieve the best possible outcome. With the current options, a single treatment may not be enough to address all the symptoms and underlying causes of the disease.

What sets us apart is our promising platform of small molecules and proteins which may be used alone or in combination with exon skipping, gene editing or gene therapy technologies.

Our Pipeline

Sarcomatrix’s research pipeline consists of α7β1 integrin activators and protein replacement therapies like Laminin-111. Our medicines are developed by doctors from the University of Nevada School of Medicine and Pharmacology in collaboration with the University of Illinois and the University of Minnesota. Although millions have been invested in our three lead therapies, more work is needed to complete pre-clinical research and move on to in-human trials.

Discovery

Preclinical

IND Enabling

Clinical Phase 1

Clinical Phase 2

Clinical Phase 3

S-969

Duchenne Muscular Dystrophy

Becker Muscular Dystrophy

Limb Girdle Muscular Dystrophy

Sunitinib

Duchenne Muscular Dystrophy

Becker Muscular Dystrophy

MD Cardiac Myopathy

LAM 111

Congenital Muscular Dystrophy

S-969

Duchenne Muscular Dystrophy

Discovery

Preclinical

IND Enabling

Clinical Phase 1

Clinical Phase 2

Clinical Phase 3

Becker Muscular Dystrophy

Discovery

Preclinical

IND Enabling

Clinical Phase 1

Clinical Phase 2

Clinical Phase 3

Limb Girdle Muscular Dystrophy

Discovery

Preclinical

IND Enabling

Clinical Phase 1

Clinical Phase 2

Clinical Phase 3

Sunitinib

Duchenne Muscular Dystrophy

Discovery

Preclinical

IND Enabling

Clinical Phase 1

Clinical Phase 2

Clinical Phase 3

Becker Muscular Dystrophy

Discovery

Preclinical

IND Enabling

Clinical Phase 1

Clinical Phase 2

Clinical Phase 3

MD Cardiac Myopathy

Discovery

Preclinical

IND Enabling

Clinical Phase 1

Clinical Phase 2

Clinical Phase 3

LAM 111

Congenital Muscular Dystrophy

Discovery

Preclinical

IND Enabling

Clinical Phase 1

Clinical Phase 2

Clinical Phase 3

Testimonials

“After living on government grants for many years, we look forward to accelerating the development of at least one of our late-stage Pre-IND programs with the support of investors. My hope is that these treatments will offer immediate benefits to individuals living with muscular dystrophy who need to be helped.”

Invest in a Better Tomorrow

Help accelerate our path to affordable therapies.

Let's Talk